P‐glycoprotein imaging in temporal lobe epilepsy: In vivo PET experiments with the Pgp substrate [11C]‐verapamil

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Epilepsia

• Publication date

  2012-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1528-1167.2012.03704.xPMID 23134497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood–Brain Barrier

  2011cited by this paper
• Tariquidar inhibition of P-glycoprotein activity in patients with temporal lobe epilepsy measured with PET and (R)-[C-11]Verapamil

  2010cited by this paper
• Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Blood–Brain Barrier

  2010cited by this paper
• Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET

  2010influential reference
• Regional P‐Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission Tomography

  2010influential reference
• Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.

  2010cited by this paper
• A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PET

  2009influential reference
• Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain.

  2008cited by this paper
• Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with (R)-11C-Verapamil and PET

  2008cited by this paper
• Pharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein Substrate R‐[11C]verapamil

  2007cited by this paper
• Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients

  2007influential reference
• Drug resistance in brain diseases and the role of drug efflux transporters

  2005cited by this paper
• Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.

  2002cited by this paper
• Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

  1999cited by this paper
• 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein.

  1998cited by this paper
• Lung cancer--management and outcome in Glasgow, 1991-92.

  1998cited by this paper
• MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy

  1995cited by this paper
• A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

  1976cited by this paper

• PET-based radiopharmaceuticals for imaging the expression and function of multidrug resistance P-glycoprotein.

  2026cites this paper
• New Radiopharmaceutical Tools in Imaging.

  2025cites this paper
• Potential clinical and biochemical markers for the prediction of drug-resistant epilepsy: A literature review.

  2022cites this paper
• Current Principles in the Management of Drug-Resistant Epilepsy

  2022cites this paper
• A new approach to produce [18F]MC225 via one-step synthesis, a PET radiotracer for measuring P-gp function

  2021cites this paper
• Recent Developments in Diagnosis of Epilepsy: Scope of MicroRNA and Technological Advancements

  2021cites this paper
• A New Approach To Produce [18F]MC225 Via One-Step Synthesis, A PET Radiotracer For Measuring P-gp Function.

  2021cites this paper
• PET Imaging of ABC Transporters at the Blood-Brain Barrier

  2020cites this paper
• A Novel Approach to Refractory Epilepsy by Targeting Pgp peripherally and centrally: Therapeutic targets and Future perspectives.

  2020cites this paper
• Pharmacoresistance - Epidemiology, Mechanisms, And Impact On Epilepsy Treatment.

  2020cites this paper
• Konzept Pharmakoresistenz

  2020cites this paper
• Possible interplay between the theories of pharmacoresistant epilepsy

  2020cites this paper
• Newest Targets for Anticonvulsant Agents: An Overview

  2019cites this paper
• Screening therapeutics according to their uptake across the blood‐brain barrier: A high throughput method based on immobilized artificial membrane liquid chromatography‐diode‐array‐detection coupled to electrospray‐time‐of‐flight mass spectrometry

  2018cites this paper
• P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy.

  2017cites this paper
• Acetazolamide Suppresses Multi-Drug Resistance-Related Protein 1 and P-Glycoprotein Expression by Inhibiting Aquaporins Expression in a Mesial Temporal Epilepsy Rat Model

  2017cites this paper
• Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy

  2017cites this paper
• Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy.

  2017cites this paper
• Topología molecular aplicada al reconocimiento de sustratos de la Proteína de Resistencia del Cáncer de Mama (BCRP)

  2016influential citation
• PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies.

  2016cites this paper
• Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography.

  2016cites this paper
• Chapter 2 . 2 Altered GABAA receptor density and unaltered blood-brain barrier [ 11 C ] fl umazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis

  2016cites this paper
• Chapter 3 . 1 Radiation dose of the novel Pgp tracer [ 11 C ] laniquidar

  2016cites this paper
• Advances of Molecular Imaging in Epilepsy

  2016cites this paper
• The possible use of the L-type calcium channel antagonist verapamil in drug-resistant epilepsy

  2016cites this paper
• Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.

  2016cites this paper
• Discovering New Antiepileptic Drugs Addressing the Transporter Hypothesis of Refractory Epilepsy: Ligand-Based Approximations

  2016cites this paper
• Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly.

  2015cites this paper
• Multimodal imaging in nonlesional medically intractable focal epilepsy.

  2015cites this paper
• Reversal of P‐glycoprotein overexpression by Ginkgo biloba extract in the brains of pentylenetetrazole‐kindled and phenytoin‐treated mice

  2015cites this paper
• in drug-resistant epilepsy patients with mesial temporal sclerosis

  2015cites this paper
• Altered GABAA receptor density and unaltered blood–brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis

  2015cites this paper
• Disease Modification in Epilepsy: From Animal Models to Clinical Applications

  2015cites this paper
• The relationship between neurocysticercosis and epilepsy: an endless debate.

  2014cites this paper
• Avaliação do envolvimento das bombas de efluxo na fármaco-resistência ao praziquantel em Schistosoma Mansonii

  2014cites this paper
• Role of blood-brain barrier in temporal lobe epilepsy and pharmacoresistance.

  2014cites this paper
• What does a picture tell? In vivo imaging of ABC transporter function.

  2014cites this paper
• Quantitative targeted absolute proteomics (QTAP)-based rational research on the human blood-brain barrier transport

  2013cites this paper
• Radiation Dose of the P-Glycoprotein Tracer 11C-Laniquidar

  2013cites this paper
• New avenues for anti-epileptic drug discovery and development

  2013cites this paper
• suMMarY, disCussiOn and future perspeCtives

  2010cites this paper
• The blood-brAIn bArrIer And P-glyCoProTeIn

  year unknowncites this paper